1. Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study. (October 2022) Authors: Saggu, G.; Stroopinsky, D.; Dudek, A.Z.; Olszanski, A.J.; Juric, D.; Dowlati, A.; Vaishampayan, U.; Assad, H.; Rodón, J.; Gibbs, J.; Green, J.; Du, Z.; Rudicell, R.; Kannan, K.; Gharavi, R.; Gomez-Pinillos, A.; Fram, R.J.; Berger, A.; Sachsenmeier, K.; Kasar, S. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S125 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗